Insider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Sells 2,187 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul K. Audhya sold 2,187 shares of KalVista Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $9.87, for a total value of $21,585.69. Following the sale, the insider now owns 97,012 shares in the company, valued at $957,508.44. This trade represents a 2.20 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

KalVista Pharmaceuticals Trading Up 1.1 %

Shares of NASDAQ:KALV traded up $0.11 during trading on Wednesday, hitting $10.09. 162,899 shares of the stock were exchanged, compared to its average volume of 483,293. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.39 and a 12-month high of $16.88. The company has a fifty day moving average price of $10.99 and a two-hundred day moving average price of $11.94. The company has a market cap of $436.09 million, a PE ratio of -2.83 and a beta of 0.92.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.04. Equities research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -2.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on KALV. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, September 6th. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, September 9th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research note on Monday, October 7th.

Institutional Trading of KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in KALV. Barclays PLC boosted its position in KalVista Pharmaceuticals by 418.5% during the 3rd quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock worth $778,000 after purchasing an additional 54,257 shares during the period. Geode Capital Management LLC raised its stake in KalVista Pharmaceuticals by 3.1% during the third quarter. Geode Capital Management LLC now owns 830,984 shares of the specialty pharmaceutical company’s stock worth $9,624,000 after acquiring an additional 24,713 shares during the period. Zimmer Partners LP raised its stake in KalVista Pharmaceuticals by 52.6% during the third quarter. Zimmer Partners LP now owns 95,704 shares of the specialty pharmaceutical company’s stock worth $1,108,000 after acquiring an additional 33,000 shares during the period. Wellington Management Group LLP raised its stake in KalVista Pharmaceuticals by 40.3% during the third quarter. Wellington Management Group LLP now owns 117,923 shares of the specialty pharmaceutical company’s stock worth $1,366,000 after acquiring an additional 33,900 shares during the period. Finally, State Street Corp raised its stake in KalVista Pharmaceuticals by 68.1% during the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock worth $14,725,000 after acquiring an additional 515,179 shares during the period.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).